Artesunate - Frantz Viral Therapeutics

Drug Profile

Artesunate - Frantz Viral Therapeutics

Latest Information Update: 11 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Georgetown University
  • Developer Frantz Viral Therapeutics
  • Class 3-ring heterocyclic compounds; Antimalarials; Artemisinins; Small molecules; Succinates
  • Mechanism of Action Cell inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Anal intraepithelial neoplasia; Cervical intraepithelial neoplasia

Most Recent Events

  • 11 May 2017 Chemical structure information added
  • 20 Apr 2017 Phase-I clinical trials in Anal intraepithelial neoplasia in USA (Rectal) (NCT03100045)
  • 10 Apr 2017 Georgetown University has patent protection for the use of artemisinins for the treatment of HPV-induced cervical dysplasia/cancer, anal cancer and head and neck cancer in Europe, and far East
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top